Impact of protease inhibitors on drug use and cost for hospital patients with HIV

Journal of Pharmacy Technology

Volumn 15, Issue 6, 1999, Pages 212-218

  Peyron, Florence ^a   Rahmouni, Saïd ^a   Flori, Angelise ^a   Moreau, Jacques ^b   Charbit, Jean Jacques ^a,c   Buès Charbit, Martine ^a   Balansard, Guy ^a,c  

^a North Hospital   (France)

^b Hopital Felix Houphouet Boigny   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; FRANCE; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LENGTH OF STAY; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; OUTPATIENT CARE;

EID: 0033426941     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512259901500610     Document Type: Article

References (30)

1. World Health Organization. Global AIDS surveillance. Weekly Epidem Report 1998;73:373-80.
2. Carpenter CQ Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998;280:78-86.
3. Peyron F, Flori A, Galliano-di Bernardo S, Moreau J, Buès-Charbit M, Balansard G. Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994. Pharm World Sci 1997;19:202-7.
4. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid Mortal Wkly Rep MMWR 1992;41(RR-17):1-19.
5. Bennett CL, Cvitanic M, Pascal A. The costs of AIDS in Los Angeles. J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:197-203.
6. Hardy AM, Rauch K, Echenberg D, Morgan WM, Curran JW. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. JAMA 1986;255:209-11.
7. Satovsky AA, Cline M, Lee PR. Medical care costs of patients with AIDS in San Francisco. JAMA 1986;256:3103-6.
8. Seage GR 3d, Landers S, Barry A, Groopman J, Lamb GA, Epstein AM. Medical care cost of AIDS in Massachusetts. JAMA 1986; 256:3107-9.
9. Trotot PM, Lamoureux P, Pialoux G. Epidémiologie et coût du SIDA en France. J Neuroradiol 1995;22:136-41.
10. Jebakumar SPR, Woolley PD, Curless E. Lifetime cost of treating a person with HIV infection. Int J STD AIDS 1995;6:444-6.
11. Brettle RP, Atkinson FI, Wilcock J, Richardson A, Lewis R, MacCallum L, et al. The cost of health care for HIV-positive patients. Int J STD AIDS 1997;8:50-3.
12. Nykamp D, Barnett CW, Lago M, Parham DL, Fernandez ES. Cost of medication therapy in ambulatory HIV-infected patients. Ann Pharmacother 1997;31:303-7
13. Anis AH, Hogg RS, Yip B, Wang XH, Montaner JS, O'Shaughnessy MV, et al. Average annual drug cost and its determinants in a population-based cohort of HIV-positive adult men and women. PharmacoEconomics 1998;13:327-36.
14. Sharp D. Vancouver AIDS meeting highlights combination attack on HIV (letter). Lancet 1996;348:115.
15. Bourdillon F, Courtial-Destembert S, Cavaignac L, Nadal JM. Traitements antirétroviraux évolution des prescriptions 1993-1997. Le Journal du SIDA 1997;97-98:26-7.
16. Bongrand MC, Penot-Ragon C, Dhiver C, Michel G, Ravaux I, et comité de rédaction. Antirétroviraux dans le SIDA. Dossier du CNIMH 1996;17(2-3):211.
17. Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health-Syst Pharm 1998;55:233-45.
18. Réseau National de Santé Publique. Surveillance du SIDA en France, situation au 31 décembre 1997. Bull Epidem Heb 1998;9:33-8.
19. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS 1997;11:F101-5.
20. Fontenay F. Les répercussions des progrès thérapeutiques. Le Journal du SIDA 1997;97-98:5-6.
21. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. PharmacoEconomics 1996;10: 109-13.
22. Michel E, Jougla E. Mortalité par SIDA en France tendances évolutives et situation en 1996. Bull Epidem Heb 1998(7 avril);14:57-9.
23. Centers for Disease Control and Prevention. Trends in AIDS incidence, deaths, and prevalence, United States, 1996. Morbid Mortal Wkly Rep MMWR 1997;46:165-73.
24. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
25. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
26. Reggy A, Wong T, Chiasson M, Simonds R, Loo V, Heffness J. Protease inhibitors and declining AIDS deaths in New York City. In: The 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
27. Lot F, Pillonel J, Pinget R, Cazein F, Gouezl P, Laporte A. Diminution brutale du nombre de cas de SIDA rôle des nouvelles stratégies thérapeutiques? Bull Epidem Heb 1997(11 mars);11:59-61.
28. Gable CB, Tierce JC, Simison D, Ward D, Motte K. Costs of HIV+/AIDS at CD4+ count disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12: 413-20.
29. Rabkin JG, Ferrando S. A "second life" agenda: psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome. Arch Gen Psychiatry 1997;54:1049-53.
30. Perdue BE, Weidle PJ, Everson-Mays RE, Bozek PS. Evaluating the cost of medications for ambulatory HIV-infected persons in association with landmark changes in antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:354-60.